Compliance and IT security teams in pharma need firm answers before approving any AI deployment that touches patient data, doctor interactions, or regulatory documentation. This FAQ addresses the questions most commonly raised during vendor security review and compliance sign-off for AI in Indian pharma.
1. How does AI in pharma stay compliant with CDSCO regulations?
AI systems stay compliant by operating within defined process boundaries — following approved product information, respecting substitution rules, and maintaining full audit trails — rather than making independent clinical or regulatory decisions. CDSCO regulations govern drug manufacturing, labeling, and pharmacovigilance reporting, and any AI tool used in these areas needs to be configured so its outputs are traceable back to approved source data, whether that is product labeling or a standard operating procedure. Well-designed pharma AI is built to support human decision-makers with faster access to accurate information, not to replace the regulatory judgment that CDSCO processes require.
2. What happens to patient data when AI is used for adherence calls or patient support programs?
Patient data used in AI adherence programs should be stored and processed according to the company's data privacy policy and applicable Indian data protection law, with access restricted to authorized systems and personnel. This means voice recordings, call transcripts, and patient identifiers need to be encrypted, access-controlled, and retained only as long as necessary for the program's purpose. Pharma companies running patient support programs typically require any AI vendor to sign a data processing agreement specifying exactly how patient information is stored, who can access it, and how it is deleted when no longer needed.
3. Can AI systems maintain the audit trails required for pharma regulatory inspections?
Yes, properly configured AI systems log every interaction, decision, and document change with timestamps, making it possible to reconstruct exactly what happened during an inspection or audit. This is particularly important for pharmacovigilance and quality documentation, where regulators expect a clear, unbroken record of how a case was reviewed and by whom. AI systems used in these workflows should be configured from the outset with audit logging as a core requirement, not an afterthought, since retrofitting audit trails after a system is already in production is far more difficult.
4. Is it safe to use AI voice systems for calls that involve doctors discussing patient cases?
AI voice systems used in doctor-facing conversations should be scoped to product information, scheduling, and administrative topics, with clear boundaries preventing the capture or processing of identifiable patient case details shared informally by a doctor. Doctors sometimes reference patient scenarios in conversation, and a well-designed AI system should be built to avoid retaining or processing such information beyond what is operationally necessary, in line with medical confidentiality expectations. Pharma companies should review call scripts and AI configuration specifically for this risk before deploying voice AI in any doctor-facing use case.
5. How is data security handled when AI processes pharmacovigilance or adverse event reports?
Adverse event data is highly sensitive and should be processed through systems with strong encryption, strict role-based access controls, and clear separation between AI-assisted extraction and the human medical review that finalizes case assessments. Because pharmacovigilance case data can include patient health information, any AI tool used to extract or triage this data must meet the same security standard the company applies to its core safety database. Vendors should be able to demonstrate encryption in transit and at rest, defined data retention policies, and a clear incident response process in case of a security event.
6. Does using AI in pharma introduce new compliance risks compared to manual processes?
AI introduces new risks primarily around explainability and error traceability — if an AI system makes an incorrect classification or extraction, the company needs a clear process to detect, correct, and document that error for regulatory purposes. Manual processes have well-understood risk profiles built up over years of practice, while AI systems require companies to establish new validation and monitoring routines to catch systematic errors early. This is manageable with proper governance — periodic accuracy audits, clear escalation paths, and human review of AI outputs in regulated workflows — but it does require a deliberate approach rather than assuming AI removes compliance risk entirely.
7. What security certifications or standards should a pharma company look for in an AI vendor?
Pharma companies should look for AI vendors with recognized information security certifications such as ISO 27001, along with a demonstrated track record of working with regulated data in healthcare or financial services contexts. Beyond certification, it is worth asking vendors specific questions about where data is hosted, whether Indian data residency requirements can be met, how data is segregated between different clients, and what the vendor's breach notification process looks like. A certification is a useful starting filter, but the detailed answers to these operational questions matter more for a final compliance decision.
8. How does AI handle data privacy for doctors' personal and prescribing information?
Doctors' contact details, prescribing patterns, and engagement history should be treated as confidential business data with restricted access, similar to how customer relationship data is handled in other regulated industries. AI systems used for e-detailing or MR support typically need this data to personalize outreach, but access should be limited to what each system component needs, and doctors' data should not be shared beyond the specific pharma company's own commercial use without appropriate basis. Pharma companies should confirm with their AI vendor exactly how doctor data is stored, whether it is used to train shared models across other clients, and how it is deleted if a doctor relationship ends or a contract is terminated.
9. Can AI be configured to prevent unauthorized or off-label information from reaching patients or doctors?
Yes, AI systems used in pharma should be configured with strict content guardrails that limit responses to approved product information and escalate any query that veers into off-label use, dosage outside approved indications, or medical advice beyond the system's scope. This is a critical compliance control because providing off-label information inappropriately can create regulatory exposure under CDSCO advertising and promotion rules. A well-implemented system treats these guardrails as a core design requirement, with regular content audits to confirm the AI is not drifting into unapproved territory as it handles more varied real-world queries over time.
10. Who is responsible if an AI system makes a compliance error in a pharma workflow?
Responsibility for AI-driven compliance errors ultimately rests with the pharma company deploying the system, which is why most companies retain human review checkpoints for any AI output that feeds into a regulatory filing, patient-facing decision, or pharmacovigilance case. Vendor contracts typically define shared responsibility, with the vendor accountable for system performance and security, and the pharma company accountable for how the system is used within its regulated processes. This is why compliance and legal teams should be involved early in defining exactly which decisions the AI can make independently versus which decisions always require human sign-off before final action.
Related Reading
Related reading
Talk to YuVerse
Discuss your compliance and data security requirements with our team: talk to us.